Trials / Completed
CompletedNCT02633033
Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 160 (actual)
- Sponsor
- Mallinckrodt · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Acthar Gel was first approved by the Food and Drug Administration in 1952. It has been used to treat many different illnesses, including multiple sclerosis. This study will observe how treatment with Acthar affected the daily lives of patients who suffer with relapsing/remitting MS. It will collect information on symptoms, recovery, treatment patterns and safety outcomes.
Detailed description
Acthar Gel (repository corticotropin injection) contains a non-bovine analogue of adrenocorticotropic hormone (ACTH) for intramuscular or subcutaneous use. It was initially approved by the FDA in 1952 and is used for multiple indications. This registry will evaluate the use of Acthar Gel for the treatment of MS exacerbations in the United States.
Conditions
Timeline
- Start date
- 2015-11-24
- Primary completion
- 2019-05-09
- Completion
- 2019-05-09
- First posted
- 2015-12-17
- Last updated
- 2019-12-09
Locations
38 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02633033. Inclusion in this directory is not an endorsement.